Preparation, biological evaluation and dosimetry studies of 175Yb-bis-phosphonates for bone pain palliation therapy
Amir R Jalilian1, Ashraf Fakhari2, Hassan Yousefnia1, Saeed Shanehsazzadeh1, Ali Bahrami-samani1, Fariba Johari-daha1, Mehdi Shafiee-ardestani2, Ali Khalaj21Radiopharmaceutical Research And Development Lab (rrdl), Radiation Application Research School, Tehran, Iran, Postal Code: 14155-13392Faculty Of Pharmacy, Tehran University Of Medical Sciences, Tehran, Iran
OBJECTIVE: Optimized production and quality control of ytterbium-175 labeled pamidronate and alendronate complexes as efficient agents for bone pain palliation has been presented.
METHODS: Yb-175 labeled pamidronate and alendronate (175Yb-PMD and 175Yb -ALN) complexes were prepared successfully at optimized conditions with acceptable radiochemical purity, stability and significant hydroxyapatite absorption. The biodistribution of complexes were checked up to 48 h demonstrating significant bone uptake ratios for 175Yb-PAM at all-time intervals which in case of 175Yb-ALN mostly washed out through the kidneys and has been excreted.
RESULTS: 175Yb-PAM performance in animal model was better or comparable to other 175Yb-bone seeking complexes ever reported.
CONCLUSION: Based on calculations, the total body dose for 175Yb-ALN is 40% higher compared to 175Yb-PAM (esp. kidneys) indicating that 175Yb-PAM is a possible safer agent than 175Yb-ALN.
Sorumlu Yazar: Amir R Jalilian, Iran
| ARAÇLAR |
 Yazdır Alıntıyı İndir RIS EndNote BibTex Medlars Procite Reference Manager E-Postala Paylaş Yazara e-posta gönder
Benzer makaleler Google Scholar |